BOSTON and SAN DIEGO — September 10, 2025 — Leads & Copy — Rapport Therapeutics, Inc. (Nasdaq: RAPP) announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $26.00 per share.
All shares in the offering are being sold by Rapport. Rapport has granted the underwriters a 30-day option to purchase up to an additional 1,442,307 shares of its common stock at the public offering price.
The gross proceeds from the offering are expected to be approximately $250.0 million, excluding any exercise of the underwriters’ option. The offering is expected to close on or about September 11, 2025, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen and Stifel are acting as joint book-running managers for the offering.
The securities are being offered pursuant to an effective shelf registration statement previously filed with the SEC.
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders.
Julie DiCarlo
Head of Communications & IR
jdicarlo@rapportrx.com
Source: Rapport Therapeutics
